dgk alpha/zeta inhibitor incb177054
Generic: DGK Alpha/Zeta Inhibitor INCB177054
dgk alpha/zeta inhibitor incb177054: 1 clinical trial tracked.
dgk alpha/zeta inhibitor incb177054 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about dgk alpha/zeta inhibitor incb177054, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A Phase 1/2, Open-Label, Multicenter Study of INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs)
Interventionalopen9 enrolledStarted 2025-06Completion 2026-079 sites · United StatesIncyte Corporation